# Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma

> **NCT00227669** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 90 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** docetaxel
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00227669
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2010-02
- **Final completion:** 2012-08
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2016-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227669, "Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00227669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*